Psoriasis is a multifactorial skin disease involving abnormal cell proliferation and inflammation; an efficacious topical treatment is yet to be identified. A topical formulation containing 1% naltrexone HCl in xematop base was compounded, characterized and evaluated in vitro as a possible treatment for psoriasis. A three-dimensional psoriasis tissue model was exposed to the formulation for 2 or 5 days and analyzed for the level of markers of cellular proliferation, and inflammatory cytokine IL-6. Using immunohistochemical staining, the level of Ki67 protein significantly decreased in the drug-treated tissues. Western blot analysis showed 86% and 53% down-regulation of other proliferation markers PCNA and CYCLIN D1, respectively, after 5-day exposure. The pro-survival Wnt/b-catenin pathway was compromised as indicated by 57% decrease in the level of b-CATENIN and down-regulation of its downstream targets including CYCLIN D1 (decreased by 53%), c-MYC (63%), c-JUN (92%) and MET (96%) proteins. Likewise, the PI3K/AKT/mTOR pathway was significantly inhibited by 1% naltrexone HCl in xematop, suggesting protein synthesis was affected. The production of IL-6 was inhibited by 70% in drug-treated tissues. These results suggest that the compounded drug is efficacious in down-regulating molecular markers associated with the pathogenesis of psoriasis. Low-dose naltrexone in xematop was stable within 180 days when stored under refrigerated or ambient conditions. These results provide a basis for a clinical evaluation of 1% naltrexone HCl in xematop in psoriasis patients. The real-world effectiveness of dupilumab in AD based on the IGA and PNRS measures was assessed via Modernizing Medicine's Electronic Medical Assistant dermatology-specific medical records for patients age!18, !1 dupilumab prescription between 01APR17-30NOV17 and with recorded IGA and PNRS scores 3months pre-and !4months post-dupilumab initiation. Pre-vs. post-dupilumab improvements in IGA and PNRS were evaluated in patients with baseline IGA!3 and PNRS!3 (moderate-to-severe AD), respectively. Of 211 and 89 patients with recorded IGA and PNRS scores, respectively, 187(88%) with IGA!3 and 61(69%) with PNRS!3 were analyzed. Mean (SD) age was 42.3(AE17.3) and 46.9(AE16.8) years, 51% were male in both groups, and 44% and 43% were White, in the IGA!3 and PNRS!3 groups, respectively. Treatments 1-year pre-dupilumab for IGA!3 and PNRS!3 were, respectively: topical corticosteroids 69% and 85%, topical calcineurin inhibitors 19% and 25%, oral/injectable steroids 39% and 59%, systemic immunosuppressants 25% and 31%, phototherapy 11% and 8%, PDE-4 inhibitors 27% and 25%. Baseline IGA distribution was: 35% for IGA3, 54% for IGA4 and 11% for IGA5. Post-dupilumab, in IGA!3 32% of patients achieved IGA0-1; 58% and 79% achieved IGA improvements !2-points and !1-point, respectively. Baseline PNRS distribution for patients with PNRS!3 was: 47% for PNRS3-6, 53% for PNRS7-10. Post-dupilumab, in PNRS!3 PNRS improved by [mean (SD),%change] -3.6(AE3.5),-54% (p<.0001); 66% had !3-point PNRS improvement. A majority of moderate-to-severe AD patients treated with dupilumab in routine clinical practice achieved clinically meaningful improvements in AD signs and itch. Improvements observed in real-world clinical practice were comparable to those seen in dupilumab trials.
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BET inhibitor OTX015 reduces imiquimod-induced mouse psoriasiform dermatitis X Wu, S Yu, Z Shi, M Huynh, J Chong and ST Hwang Dermatology, UCDAVIS, Sacramento, California, United States Bromodomain and extra-terminal (BET) proteins perform a key role in epigenetic control of gene expression that is involved in malignant and inflammatory diseases. Recently, therapeutic targeting of BET bromodomains has been proposed to have utility in Th17-mediated pathology, including autoimmune diseases such as psoriasis. Herein, we used a BET inhibitor, OTX015, in a mouse model of imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) to determine immunological changes and therapeutic efficacy in this IL-17-dependent preclinical model of psoriasis. Mice were topically treated with IMQ over 6 days and either orally administered OTX015 at 25 mg/kg/day or control, starting from day 1 of IMQ treatment. After 6 days of treatment, OTX015-treated mouse skin showed decreased skin disease severity, scale, ear thickness, and transepidermal water loss compared to vehicle-treated mice. Flow cytometric analysis of OTX015 treated-ear skin revealed a w50% decrease of neutrophil (CD11b+Ly6G+) infiltration. In addition, cervical lymph nodes in OTX015-treated mice contained significantly fewer CD45+ vg4+ gd-T cells (i.e, major producers of IL-17A in murine PsD models). Splenomegaly has been observed in IMQ-treated mice, and systemic OTX015 treatment almost completely normalized splenic size and weight. Of note, mice did not show significant activity change or weight loss (vs. control-treated mice) after 6 days of OTX015 treatment. In summary, our results suggest that OTX015 can be safely administered in mice and may provide significant anti-inflammatory benefit that reduces clinical and immunological signs of PsD in IMQ-treated mice. Further investigation of BET proteins as treatment for psoriasis in humans is thus warranted.
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Equol's efficacy is greater than astaxanthin for antioxidants, extracellular matrix integrity & breakdown, growth factors and inflammatory biomarkers via human skin gene expression analysis E Lephart PDBio Department, College of Life Sciences, Brigham Young University, Provo, Utah, United States Skin homeostasis and aging represent complex molecular and chemical biological processes that are influenced by endogenous and exogenous factors. Numerous plant-derived compounds are known to exert positive actions on skin health. Astaxanthin (asta) is a known powerful antioxidant and anti-inflammatory skin agent, while equol's beneficial dermal health properties have been recently reported. In this in vitro study, asta was compared to equol to determine the effects of each phytochemical via human skin gene expression by quantitative qPCR-mRNA analysis. Asta or equol @ 1.0 % were dissolved in dimethyl sulfoxide (DMSO) and topically applied to epidermal full-thickness (EFT) skin cultures for 24 hours. Where appropriate, the treatment groups were compared to each other and the DMSO vehicle. Overall, 90 skin target biomarkers were analyzed across 9 skin function categories; 63 genes (or 70 % of the total) are reported here. In 39 skin biomarkers equol significantly altered (increased or decreased) the parameters in a positive manner compared to asta. Asta significantly influenced 6 dermal genes compared to equol and 18 of the skin biomarkers were not significantly different between the two treatment groups. The most striking results displayed significantly greater effects of equol compared to asta for the antioxidants (AHR,  GPX1 . These findings reveal that equol's efficacy is greater than asta for various gene biomarkers suggesting that equol may be incorporated into topical and oral applications to improve skin health and reduce photo-aging.
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Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata Z Dai, E Loesch, JC Chen, E Wang, E Lee and A Christiano Dermatology, Columbia University, New York, New York, United States Dysregulation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway has pathological implications in autoimmune diseases. We found that therapeutic targeting of JAK/STAT pathways using first-generation JAK1/2 inhibitor (ruxolitinib) or pan-JAK inhibitor (tofacitinib) were effective in the treatment of human AA and in the C3H/HeJ mouse model. To further understand the role of individual JAK in AA and to produce the desired antiinflammatory effects without unnecessary inhibition of other JAK pathways, we used JAKselective inhibitors (JAK1-selective inhibitor Itacitinib, JAK2-selective inhibitor CEP33779 and JAK3-selective inhibitor PF06651600) to treat C3H/HeJ mice with AA. We demonstrate that JAK1-selective inhibitors as well as JAK3-selective inhibitors are effective in reversal of alopecia in C3H/HeJ mice with AA. In contrast, JAK2-selective inhibitor failed to restore hair regrowth. JAK1-seletive inhibition and JAK3-seletive inhibition was associated with decreased skin immune cells infiltration, reduced pathogenic cell responses and analysis of RNAseq data of whole skin biopsies taken from the JAK inhibitors treated-mice revealed statistically independent (orthogonal at FDR<0.05) molecular response profiles reflecting the variable efficacy of each JAK inhibitor type. JAK1 and JAK3 inhibitors (but not JAK2 inhibitors or controls) exhibited normalized gene expression patterns similar to unaffected C3H/HeJ mice, indicating JAK1 and JAK3 inhibition suppressed the dermal inflammatory/ cytotoxic T cell signature for AA reversal. Our results contribute to a more refined understanding of JAK1 or JAK3 inhibition as a therapeutic target in AA treatment, and suggest that inhibition of JAK2 is not required for treatment efficacy in AA.
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A straightforward preclinical efficacy assessment approach to identify promising drug candidates for development of novel topical anti-inflammatory drugs M Soeberdt, A Kilic and C Abels Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany Besides being the biggest barrier organ of our body, skin also has an important neuroimmuno-endocrine function. Chronic inflammatory skin diseases represent a global health problem. Thus, the search for new anti-inflammatory locally applied, locally acting, nonimmunosuppressive drug candidates with improved side-effect profile is of great importance. Here, we present a strategy for research and development of anti-inflammatory drugs for topical as well as systemic application. Compounds of interest (NME, repurposing or repositioning of known APIs) should target general immunomodulatory and not specific diseasebound pathways and should exhibit particular phys.-chem. characteristics, e.g. molecular size, lipophilicity, and topological polar surface area. Moreover, pI and selectivity of the target are also of importance. Once phys.-chem. properties are optimized, compounds are tested in a core set of in vitro experiments on human and murine epithelial and immune cells (T-cells, keratinocytes) including cytotoxicity assessment to ensure that findings in mice are not species-specific. Following prove of the anti-inflammatory activity in vitro, they are tested in a set of in vivo "unspecific" acute and chronic models of dermatitis (mouse models of arachidonic acid-induced ear edema and oxazolone-induced DTH). Promising compounds with anti-inflammatory action are tested in models of other skin diseases, like mouse models of IMQinduced psoriasis-like inflammation and barrier disruption (tape striping or SDS patch). A broad, general anti-inflammatory activity is shown by testing the compound in models with different pathophysiology like the murine model of DSS-induced colitis or vasculitis (local Shwartzman-reaction). During preclinical development the candidate compound and its topical formulation are tested in more sophisticated animal models like the OVA-induced dermatitis model in mice or the canine model of atopic dermatitis. Applying this strategy we were able to nominate two clinical and two preclinical candidates.
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